MedPath

Resectability of Pancreatic Head Cancer by Contrast-enhanced MDCT:a Multi-center Study

Conditions
Adenocarcinoma of Head of Pancreas
Registration Number
NCT01455610
Lead Sponsor
Meng Su Zeng
Brief Summary

The purpose of this multicenter and double-blind clinical trial is to prospectively assess the sensitivity, specificity, negative predictive value, positive predictive value, and accuracy in respectability of pancreatic head cancer with contrasted-enhanced MDCT and its various post processing techniques, taking operational and pathological records as the gold standard.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
140
Inclusion Criteria
  • Patients with (or suspected) pancreatic head cancer
  • Being examined by contrasted-enhanced MDCT
  • Receiving surgical treatment (including palliative surgery) in all research centers
Exclusion Criteria
  • Patients having (or suspected) pregnancy or breast-feeding
  • Patients having allergic reactions to iodinated contrast agents or Hypersensitivity reactions to allergens(including drugs)
  • Patients receiving ERCP before contrasted-enhanced MDCT examination
  • Patients without surgery because of a high degree of surgical risk

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (6)

Radiology Department, Ruijing Hospital, Shanghai Jiaotong University

🇨🇳

Shanghai, Shanghai, China

Radiology Department, Cancer Hospital, Fuandan University

🇨🇳

Shanghai, Shanghai, China

Radiology Department, Zhongshan Hospital, Fudan University

🇨🇳

Shanghai, Shanghai, China

Radiology Department, Huadong Hospital, Fudan University

🇨🇳

Shanghai, Shanghai, China

Radiology Department, Huashan Hospital, Fudan University

🇨🇳

Shanghai, Shanghai, China

Radiology Department, Changhai Hospital Affiliated to the Second Military Medical University

🇨🇳

Shanghai, Shanghai, China

Radiology Department, Ruijing Hospital, Shanghai Jiaotong University
🇨🇳Shanghai, Shanghai, China
Fuhua Yan, MD, PhD
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.